2seventy bio, Inc.
2seventy bio, Inc., headquartered in the United States, is a pioneering biotechnology company focused on developing transformative cell therapies for cancer treatment. Founded in 2020, the company has quickly established itself in the biopharmaceutical industry, particularly in the areas of engineered cell therapies and innovative drug development. With a commitment to advancing the field of oncology, 2seventy bio's core offerings include cutting-edge therapies that harness the power of the immune system to target and eliminate cancer cells. Their unique approach combines scientific expertise with a patient-centric focus, setting them apart in a competitive market. Recognised for its rapid progress and innovative solutions, 2seventy bio is positioned as a leader in the fight against cancer, striving to improve patient outcomes and redefine treatment paradigms.
DitchCarbon Score
How does 2seventy bio, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
2seventy bio, Inc.'s score of 69 is higher than 83% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
2seventy bio, Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Bristol-Myers Squibb Company, which influences its climate commitments and emissions reporting. As part of its corporate family, 2seventy bio, Inc. inherits climate initiatives and targets from Bristol-Myers Squibb. This includes commitments to the Science Based Targets initiative (SBTi) and other sustainability frameworks. However, specific reduction targets or achievements for 2seventy bio, Inc. have not been disclosed. The absence of direct emissions data suggests that 2seventy bio, Inc. is in the process of establishing its own climate strategy, potentially aligning with the broader goals set by its parent company. The company is expected to contribute to the overarching sustainability efforts of Bristol-Myers Squibb, which may include significant reductions in Scope 1, 2, and 3 emissions as part of their corporate responsibility initiatives. In summary, while 2seventy bio, Inc. does not currently report specific emissions figures or reduction targets, it is positioned within a framework of climate commitments inherited from Bristol-Myers Squibb, indicating a commitment to sustainability and emissions reduction in the future.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 210,540,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 150,790,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | 69,630,000 | 00,000,000 | 00,000,000 | 00,000,000 | 000,000,000 | 00,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
2seventy bio, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
